How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
Read time: 5 minutes.
This is Part 3 in our series on how drugs get approved to treat lung cancer.
How We Define Success for a Clinical Trial
Read time: 6 minutes.
This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are important for new drug development.
Understanding Clinical Trials: Why Are They Important for Drug Development?
Read time: 3 minutes.
This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming weeks.
Have you ever wondered how a new medicine or drug to treat lung cancer is brought to the people who need it? That’s what clinical trials help us do.
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Read time: 3 minutes.
One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment.
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes.
Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials.
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Read time: 2 minutes
Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods.
LUNGevity spoke to an expert to help sort out the facts from the fiction.
New Treatment Approved for Early-Stage ALK+ Lung Cancer
On April 18, 2024, the US Food and Drug Administration (FDA) announced the approval of alectinib to treat patients after surgical removal of ALK-positive non-small cell lung cancer (NSCLC).
The approval is supported by data from the phase 3 ALINA trial, which showed that treating patients with alectinib reduced the risk of disease recurrence by 76% compared to treating them with chemotherapy.
Alectinib is approved for use in patients with completely resected stage IB to IIIA ALK-positive NSCLC whose tumors are at least 4 cm wide.
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr.
Lung Cancer Masterclass: Get Smart About Lung Cancer
In the past five years, the lung cancer community has seen an astonishing number of new treatments. As our understanding of lung cancer has deepened, the older treatment approaches have also become more effective and efficient.
These options are fantastic steps toward improving the overall survival and quality of life for people living with lung cancer, but it can be difficult for patients and caregivers to keep track of the new drug treatments and scientific advancements.